You are called for a patient with hypotension, fever, and a rising lactate.
No clear source. No culture data. No time.
You are not confirming a diagnosis. You are deciding coverage.
Start With the Real Question
This is not "what is the diagnosis."
This is: what organisms can kill this patient in the next few hours, and what do I need to cover right now.
In sepsis with unknown source, that usually means:
•
Gram negatives, including Pseudomonas
•
Gram positives, including MRSA
•
Anaerobes, depending on context
Everything else is secondary.
Default Backbone: Broad Gram-Negative Coverage
In unstable patients, you need reliable gram-negative coverage first.
Typical backbone options:
•
Meropenem in high-risk or ESBL concern
Choice depends on:
•
Local resistance patterns
•
Prior antibiotic exposure
Ceftriaxone is not enough here if the patient is unstable.
When to Add MRSA Coverage
Do not add vancomycin reflexively. Add it when it matters.
Indications:
•
Skin or soft tissue source
•
Severe sepsis without clear source
If you are wrong and omit MRSA, the cost can be high.
Anaerobic Coverage
This depends on suspected source.
Include anaerobes if:
•
Intra-abdominal infection
Zosyn and carbapenems already cover this. Cefepime does not.
Zosyn vs Cefepime: The Real Difference
This is a common decision point.
Piperacillin-tazobactam (Zosyn)
Covers anaerobes, slightly broader empiric coverage
Often chosen when source unclear
Strong gram-negative coverage including Pseudomonas
No anaerobic coverage; pair with metronidazole if needed
Neither is universally better. It depends on what you are trying to cover.
When to Escalate to Carbapenems
Reserve for:
•
Recent broad-spectrum antibiotic exposure
•
High-risk healthcare-associated infection
•
Clinical deterioration despite appropriate therapy
Do not start here routinely. Use it when risk justifies it.
The Timing Matters More Than the Perfect Choice
In sepsis, delay in appropriate antibiotics increases mortality.
A good regimen started now is better than a perfect regimen started later.
You are optimizing under time pressure, not solving a completed case.
De-escalation Is Not Optional
Once cultures return:
•
Adjust based on susceptibilities
Failure to de-escalate is how resistance develops in practice.
Where This Actually Gets Difficult
Not in theory. In execution.
You are:
•
Managing multiple patients
•
Working with incomplete data
•
Under pressure to act quickly
You know the principles. The difficulty is applying them immediately and consistently.
For a Broader Look at Why This Is Getting Harder
Antibiotic resistance is changing what "adequate coverage" even means. See our article on why antibiotics are losing effectiveness for a deeper look at the mechanisms shaping empiric therapy decisions today.
What Actually Helps at the Bedside
In this moment, you need:
•
Immediate access to regimens
•
Confidence that you are not missing something critical
Not a full guideline. Not a long explanation. A decision you can act on.
DUK-C is built around this exact scenario. Rapid empiric antibiotic pathways, clear coverage frameworks, and guideline-based regimens you can use immediately.
For Clinicians
DUK-C provides:
•
Rapid empiric antibiotic pathways
•
Clear coverage frameworks
•
Guideline-based regimens you can use immediately
So when the source is unclear, the decision is not.
Join Early Access
If you have ever had to start broad-spectrum antibiotics without a diagnosis and no time to hesitate, you already understand the problem. DUK-C is built for that exact moment.
Join early access to get first access to clinical decision tools, improve speed and confidence at the bedside, and help shape the platform.